Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells

OncoImmunology

Volumn 5, Issue 1, 2016, Pages

  Haabeth, Ole Audun Werner ^a   Lorvik, Kristina Berg ^a   Yagita, Hideo ^b   Bogen, Bjarne ^a,c   Corthay, Alexandre ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

And IL33; Cancer immunosurveillance; CD4+ T cells; IFN ; IL 1RA; IL 1 ; IL 21; IL 27; Inflammation; Macrophages; Th1

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 27; INTERLEUKIN 33; MATRIGEL; THYMIDINE DERIVATIVE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ERADICATION; FLOW CYTOMETRY; GROWTH INHIBITION; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; MOUSE; MYELOMA; NONHUMAN; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84954453058     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1039763     Document Type: Article

References (72)

1. Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005; 22:371-83; PMID:15780993; http://dx. doi. org/10. 1016/j. immuni. 2005. 02. 003
2. Galon J, Costes A, Sanchez-Cabo F, KirilovskyA, MlecnikB, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx. doi. org/ 10. 1126/science. 1129139
3. Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sorlie T, Warnberg F, Haakensen VD, Helland A et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A 2012; 109:2802-7; PMID:21908711; http://dx. doi. org/ 10. 1073/pnas. 1108781108
4. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344:641-5; PMID:24812403; http://dx. doi. org/10. 1126/science. 1251102
5. Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A et al. How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules? Front Immunol 2014; 5:174; PMID:24782871; http://dx. doi. org/ 10. 3389/fimmu. 2014. 00174
6. Corthay A. Does the Immune System Naturally Protect Against Cancer? Front Immunol 2014; 5:197; PMID:24860567; http://dx. doi. org/10. 3389/fimmu. 2014. 00197
7. Schreiber RD, Pace JL, Russell SW, Altman A, Katz DH. Macrophage-activating factor produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to gamma-interferon. Journal of immunology 1983; 131:826-32; PMID:NOT_FOUND
8. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23:549-55; PMID:12401408; http://dx. doi. org/10. 1016/S1471-4906(02)02302-5
9. Haabeth OA, Bogen B, Corthay A. A model for cancersuppressive inflammation. Oncoimmunology 2012; 1:1146-55; PMID:23170261; http://dx. doi. org/ 10. 4161/onci. 21542
10. Mantovani A, Allavena P, Sica A, Balkwill F. Cancerrelated inflammation. Nature 2008; 454:436-44; PMID:18650914; http://dx. doi. org/10. 1038/nature 07205
11. HeusinkveldM, de Vos van Steenwijk PJ, Goedemans R, Ramwadhdoebe TH, Gorter A, Welters MJ, van Hall T, van der Burg SH. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol 2011; 187:1157-65; PMID:21709158; http:// dx. doi. org/10. 4049/jimmunol. 1100889
12. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013; 339:286-91; PMID:23329041; http://dx. doi. org/10. 1126/science. 1232227
13. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16:91-102; PMID:19647220; http://dx. doi. org/10. 1016/j. ccr. 2009. 06. 018
14. Bogen B, Gleditsch L, Weiss S, Dembic Z. Weak positive selection of transgenic T cell receptor-bearing thymocytes: importance of major histocompatibility complex class II, T cell receptor and CD4 surface molecule densities. Eur J Immunol 1992; 22:703-9; PMID:1547816; http://dx. doi. org/10. 1002/eji. 1830220313
15. Lauritzsen GF, Weiss S, Dembic Z, Bogen B. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A 1994; 91:5700-4; PMID:7911244; http://dx. doi. org/ 10. 1073/pnas. 91. 12. 5700
16. Bogen B, Munthe L, Sollien A, Hofgaard P, Omholt H, Dagnaes F, Dembic Z, Lauritzsen GF. Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies. Eur J Immunol 1995; 25:3079-86; PMID:7489746; http://dx. doi. org/ 10. 1002/eji. 1830251114
17. Corthay A, Lundin KU, Lorvik KB, Hofgaard PO, Bogen B. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. Cancer research 2009; 69:5901-7; PMID:19567679; http://dx. doi. org/10. 1158/0008-5472. CAN-08-4816
18. Haabeth OA, Lorvik KB, Hammarstrom C, Donaldson IM, Haraldsen G, Bogen B, Corthay A. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun 2011; 2:240; PMID:21407206; http://dx. doi. org/10. 1038/ncomms1239
19. Lorvik KB, Bogen B, Corthay A. Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice. Blood 2012; 119:2176-7; PMID:22383793; http://dx. doi. org/ 10. 1182/blood-2011-10-388892
20. Lorvik KB, Haabeth OAW, Clancy T, Bogen B, Corthay A. Molecular profiling of tumor-specific Th1 cells activated in vivo. OncoImmunology 2013; 2:e24383; PMID:23762808; http://dx. doi. org/10. 4161/onci. 24383
21. Peri G, Polentarutti N, Sessa C, Mangioni C, Mantovani A. Tumoricidal activity of macrophages isolated from human ascitic and solid ovarian carcinomas: augmentation by interferon, lymphokines and endotoxin. Int J Cancer 1981; 28:143-52; PMID:6172388; http://dx. doi. org/10. 1002/ ijc. 2910280206
22. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-11; PMID:11323675; http://dx. doi. org/10. 1038/ 35074122
23. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998; 95:7556-61; PMID:9636188; http://dx. doi. org/ 10. 1073/pnas. 95. 13. 7556
24. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975; 72:3666-70; PMID:1103152; http://dx. doi. org/ 10. 1073/pnas. 72. 9. 3666
25. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999; 189:1343-54; PMID:10209050; http://dx. doi. org/10. 1084/jem. 189. 8. 1343
26. Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H. Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med 2000; 192:1373-80; PMID:11067885; http://dx. doi. org/10. 1084/jem. 192. 9. 1373
27. Halaas O, Vik R, Ashkenazi A, Espevik T. Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages. Scand J Immunol 2000; 51:244-50; PMID:10736093; http://dx. doi. org/ 10. 1046/j. 1365-3083. 2000. 00671. x
28. Granowitz EV, Porat R, Mier JW, Pribble JP, Stiles DM, Bloedow DC, Catalano MA, Wolff SM, Dinarello CA. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992; 4:353-60; PMID:1420996; http://dx. doi. org/10. 1016/ 1043-4666(92)90078-6
29. Nakamura S, Nakata K, Kashimoto S, Yoshida H, Yamada M. Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors. Jpn J Cancer Res 1986; 77:767-73; PMID:3093425
30. North RJ, Neubauer RH, Huang JJ, Newton RC, Loveless SE. Interleukin 1-induced, T cell-mediated regression of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity. J Exp Med 1988; 168:2031-43; PMID:3143799; http://dx. doi. org/10. 1084/jem. 168. 6. 2031
31. Voronov E, Weinstein Y, Benharroch D, Cagnano E, Ofir R, Dobkin M, White RM, Zoller M, Barak V, Segal S et al. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression. Cancer Res 1999; 59:1029-35; PMID:10070959
32. Song X, Voronov E, Dvorkin T, Fima E, Cagnano E, Benharroch D, Shendler Y, Bjorkdahl O, Segal S, Dinarello CA et al. Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. J Immunol 2003; 171:6448-56; PMID:14662844; http://dx. doi. org/10. 4049/jimmunol. 171. 12. 6448
33. Von Stebut E, Ehrchen JM, Belkaid Y, Kostka SL, Molle K, Knop J, Sunderkotter C, Udey MC. Interleukin 1alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. J Exp Med 2003; 198:191-9; PMID:12860932; http://dx. doi. org/10. 1084/jem. 20030159
34. Ben-Sasson SZ, Hu-Li J, Quiel J, Cauchetaux S, Ratner M, Shapira I, Dinarello CA, Paul WE. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci U S A 2009; 106:7119-24; PMID:19359475; http://dx. doi. org/10. 1073/pnas. 0902745106
35. Koide SL, Inaba K, Steinman RM. Interleukin 1 enhances T-dependent immune responses by amplifying the function of dendritic cells. J Exp Med 1987; 165:515-30; PMID:2950198; http://dx. doi. org/ 10. 1084/jem. 165. 2. 515
36. Ben-Sasson SZ, Hogg A, Hu-Li J, Wingfield P, Chen X, Crank M, Caucheteux S, Ratner-Hurevich M, Berzofsky JA, Nir-Paz R et al. IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J Exp Med 2013; 210:491-502; PMID:23460726; http://dx. doi. org/10. 1084/jem. 20122006
37. Schultz RM, Kleinschmidt WJ. Functional identity between murine gamma interferon and macrophage activating factor. Nature 1983; 305:239-40; PMID:6412144; http://dx. doi. org/10. 1038/305239a0
38. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C et al. Defective LPS signaling in C3H/HeJ and C57BL/ 10ScCr mice: mutations in Tlr4 gene. Science 1998; 282:2085-8; PMID:9851930; http://dx. doi. org/ 10. 1126/science. 282. 5396. 2085
39. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci U S A 1998; 95:588-93; PMID:9435236; http://dx. doi. org/ 10. 1073/pnas. 95. 2. 588
40. Hori K, Mihich E, Ehrke MJ. Role of tumor necrosis factor and interleukin 1 in gamma-interferon-promoted activation of mouse tumoricidal macrophages. Cancer Res 1989; 49:2606-14; PMID:2496917
41. Niinobu T, Fukuo K, Yasuda O, Tsubakimoto M, Mogi M, Nishimaki H, Morimoto S, Ogihara T. Negative feedback regulation of activated macrophages via Fas-mediated apoptosis. American journal of physiology Cell physiology 2000; 279:C504-9; PMID:10913017
42. Petrella TM, Tozer R, Belanger K, Savage KJ, Wong R, Smylie M, Kamel-Reid S, Tron V, Chen BE, Hunder NN et al. Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol 2012; 30:3396-401; PMID:22915661; http://dx. doi. org/10. 1200/JCO. 2011. 40. 0655
43. Santegoets SJ, Turksma AW, Powell Jr DJ, Hooijberg E, de Gruijl TD. IL-21 in cancer immunotherapy: At the right place at the right time. Oncoimmunology 2013; 2:e24522; PMID:23894713; http://dx. doi. org/ 10. 4161/onci. 24522
44. Bhatia S, Curti B, Ernstoff MS, Gordon M, Heath EI, Miller WH, Jr., Puzanov I, Quinn DI, Flaig TW, Van-Veldhuizen P et al. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer 2014; 2:2; PMID:24829759; http://dx. doi. org/10. 1186/2051-1426-2-2
45. Cocco C, Giuliani N, Di Carlo E, Ognio E, Storti P, Abeltino M, Sorrentino C, Ponzoni M, Ribatti D, Airoldi I. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res 2010; 16:4188-97; PMID:20587591; http://dx. doi. org/ 10. 1158/1078-0432. CCR-10-0173
46. Zorzoli A, Di Carlo E, Cocco C, Ognio E, Ribatti D, Ferretti E, Dufour C, Locatelli F, Montagna D, Airoldi I. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/ Il2rg-/-mice. Clin Cancer Res 2012; 18:1630-40; PMID:22383738; http://dx. doi. org/10. 1158/1078-0432. CCR-11-2432
47. Swarbrick A, Junankar SR, Batten M. Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy? Oncoimmunology 2013; 2:e25409; PMID:24083081; http://dx. doi. org/10. 4161/onci. 25409
48. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM. Interleukin-33-cytokine of dual function or novel alarmin? Trends Immunol 2009; 30:227-33; PMID:19359217; http://dx. doi. org/10. 1016/j. it. 2009. 03. 003
49. Villarreal DO, Wise MC, Walters JN, Reuschel EL, Choi MJ, Obeng-Adjei N, Yan J, Morrow MP, Weiner DB. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res 2014; 74:1789-800; PMID:24448242; http://dx. doi. org/10. 1158/0008-5472. CAN-13-2729
50. Gao X, Wang X, Yang Q, Zhao X, Wen W, Li G, Lu J, Qin W, Qi Y, Xie F et al. Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment through CD8+ T and NK Cells. J Immunol 2015; 194:438-45; PMID:25429071; http:// dx. doi. org/10. 4049/jimmunol. 1401344
51. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-45; PMID:11229684; http://dx. doi. org/10. 1016/S0140-6736(00)04046-0
52. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7; PMID:12490959; http://dx. doi. org/10. 1038/nature01322
53. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883-99; PMID:20303878; http://dx. doi. org/10. 1016/j. cell. 2010. 01. 025
54. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48:526-35; PMID:11247898; http://dx. doi. org/ 10. 1136/gut. 48. 4. 526
55. Polk DB, Peek RM, Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 2010; 10:403-14; PMID:20495574; http://dx. doi. org/10. 1038/nrc2857
56. Ekstrom K, Hjalgrim H, Brandt L, Baecklund E, Klareskog L, Ekbom A, Askling J. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003; 48:963-70; PMID:12687538; http://dx. doi. org/ 10. 1002/art. 10939
57. Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 1995; 85:765-71; PMID:7530507
58. Preti HA, Cabanillas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 1997; 127:186-94; PMID:9245223; http://dx. doi. org/ 10. 7326/0003-4819-127-3-199708010-00002
59. Martin F, Santolaria F, Batista N, Milena A, Gonzalez-Reimers E, Brito MJ, Oramas J. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999; 11:80-6; PMID:10080883; http://dx. doi. org/ 10. 1006/cyto. 1998. 0398
60. Bani MR, Garofalo A, Scanziani E, Giavazzi R. Effect of interleukin-1-beta on metastasis formation in different tumor systems. J Natl Cancer Inst 1991; 83:119-23; PMID:1988686; http://dx. doi. org/10. 1093/jnci/ 83. 2. 119
61. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A 2003; 100:2645-50; PMID:12598651; http://dx. doi. org/10. 1073/pnas. 0437939100
62. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379(9826):1591-601; PMID:22440947
63. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379 (9826):1602-12; PMID:22440946
64. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13(5):518-27; PMID:22440112
65. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-13; PMID:12529460; http://dx. doi. org/10. 1056/NEJMoa020177
66. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR. Tumore1039763 infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29:1949-55; PMID:21483002; http://dx. doi. org/10. 1200/JCO. 2010. 30. 5037
67. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8; PMID:19767732; http://dx. doi. org/ 10. 1038/nm. 2028
68. Bogen B, Lauritzsen GF, Weiss S. A stimulatory monoclonal antibody detecting T cell receptor diversity among idiotype-specific, major histocompatibility complex-restricted T cell clones. Eur J Immunol 1990; 20:2359-62; PMID:1700755; http://dx. doi. org/ 10. 1002/eji. 1830201030
69. Inoue A, Koh CS, Yahikozawa H, Yanagisawa N, Yagita H, Ishihara Y, Kim BS. The level of tumor necrosis factor-alpha producing cells in the spinal cord correlates with the degree of Theiler's murine encephalomyelitis virus-induced demyelinating disease. Int Immunol 1996; 8:1001-8; PMID:8757945; http://dx. doi. org/10. 1093/intimm/8. 7. 1001
70. Wang HH, McIntosh AR, Hasinoff BB, Rector ES, Ahmed N, Nance DM, Orr FW. B16 melanoma cell arrest in the mouse liver induces nitric oxide release and sinusoidal cytotoxicity: a natural hepatic defense against metastasis. Cancer Res 2000; 60:5862-9; PMID:11059784
71. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001; 7:94-100; PMID:11135622; http://dx. doi. org/ 10. 1038/83416
72. Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K et al. Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med 2011; 2:103-8; PMID:22977477